CNR1 and metabolic syndrome: Currently, the peripheral CB1R antagonist monlunabant (MRI-1891, INV-202) is reported to be advancing to the phase IIB clinical stage after successfully completing phase IB (NCT05282446) and IIA (NCT05891834) studies in obesity and metabolic syndrome (12).